Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

• US 9,856,255 B2
• Filed: 09/16/2016
• Issued: 01/02/2018
• Est. Priority Date: 09/17/2015
• Status: Active Grant

• Current Assignee: Astrazeneca AB (Astrazeneca PLC)
• Original Assignee: Astrazeneca AB (Astrazeneca PLC)
• Inventors: Barlaam, Bernard Christophe, Pike, Kurt Gordon
• Primary Examiner(s): Mauro, Matt
• Application Number:
  US15/267,398
• Publication Number:
  US 20170081325A1
• Time in Patent Office: 473 Days
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

The specification generally relates to compounds of Formula (I):

• • and pharmaceutically acceptable salts thereof, where R¹, R², R³, R⁴ and R⁵ have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.

Claims

1. A compound which is:

7-Fluoro-1-isopropyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-one or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition, wherein the composition comprises the compound according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

3. A compound which is:

7-Fluoro-1-isopropyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-one.

4. A pharmaceutical composition, wherein the composition comprises the compound according to claim 3, and at least one pharmaceutically acceptable excipient.

5. A compound which is a pharmaceutically acceptable salt of 7-Fluoro-1-isopropyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-one.

6. A pharmaceutical composition, wherein the composition comprises the pharmaceutically acceptable salt of the compound according to claim 5, and at least one pharmaceutically acceptable excipient.